Cite
HARVARD Citation
Panaccione, R. et al. (n.d.). Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. Journal of Crohn's and colitis. pp. 930-938. [Online].